Ionis Pharmaceuticals (IONS) EBT (2009 - 2026)

Ionis Pharmaceuticals' EBT history runs 18 years deep, the most recent figure standing at -$92.3 million for Q1 2026.

• In Q1 2026, EBT rose 37.13% year-over-year to -$92.3 million; the TTM figure through Mar 2026 stood at -$326.7 million (up 29.72% YoY), while the FY2025 annual figure was -$381.2 million, up 17.26% from the prior year.
• EBT was -$92.3 million for Q1 2026 at Ionis Pharmaceuticals, up from -$229.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $123.5 million in Q2 2025 to a low of -$229.5 million in Q4 2025.
• Historically, EBT has averaged -$89.8 million across 5 years, with a median of -$102.9 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBT sank 3791.69% in 2024, then jumped 286.6% in 2025.
• A 5-year view of EBT shows it stood at -$44.8 million in 2022, then surged by 93.83% to -$2.8 million in 2023, then tumbled by 3791.69% to -$107.7 million in 2024, then slumped by 113.12% to -$229.5 million in 2025, then soared by 59.78% to -$92.3 million in 2026.
• The last three EBT figures came in at -$92.3 million (Q1 2026), -$229.5 million (Q4 2025), and -$128.4 million (Q3 2025), per Business Quant data.